FindTrial
Sign In

An epidemiological investigation of PCSK9 gene mutation and the control of drug intensification for lipid-lowering in Shanghai·

An epidemiological investigation of PCSK9 gene mutation and the control of drug intensification for lipid-lowering in Shanghai

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074657
Enrollment
Unknown
Registered
2023-08-11
Start date
2023-08-17
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipemia

Interventions

Trail group:none

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) Age 40 and above; (2) Permanent residents who have lived in Shanghai for at least 5 years; (3) no obvious mental or cognitive impairment;

Exclusion criteria

Exclusion criteria: (1) People with serious diseases; (2) Respondents who did not complete the questionnaire; (3) Those who do not want to collect blood samples;

Design outcomes

Primary

MeasureTime frame
low-density lipoprotein cholesterol;high-density lipoproteincholesterol;cholesterol;triglyceride;—

Secondary

MeasureTime frame
height;weight;Blood pressure;Heart rate;Fasting blood glucose;aminotransferase;—

Countries

CHINA

Contacts

Public ContactLi Dongjie

Shanghai Tenth People's Hospital

djli@tongji.edu.cn+86 189 1768 7625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026